Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound?

A month has gone by since the last earnings report for Beam Therapeutics Inc. (BEAM). Shares have lost about 21.4% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Beam Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns out, fresh estimates have trended downward during the past month.VGM ScoresAt this time, Beam Therapeutics has an average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions has been net zero. Notably, Beam Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.Performance of an Industry PlayerBeam Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Intra-Cellular Therapies (ITCI), has gained 2.5% over the past month. More than a month has passed since the company reported results for the quarter ended December 2024.Intra-Cellular reported revenues of $199.22 million in the last reported quarter, representing a year-over-year change of +50.8%. EPS of -$0.16 for the same period compares with -$0.30 a year ago.For the current quarter, Intra-Cellular is expected to post a loss of $0.08 per share, indicating a change of +50% from the year-ago quarter. The Zacks Consensus Estimate has changed +47.8% over the last 30 days.The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Intra-Cellular. Also, the stock has a VGM Score of B.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Beam Therapeutics Inc. (BEAM): Free Stock Analysis Report Intra-Cellular Therapies Inc. (ITCI): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks